Ramessar Koreen, Rademacher Thomas, Sack Markus, Stadlmann Johannes, Platis Dimitris, Stiegler Gabriela, Labrou Nikos, Altmann Fritz, Ma Julian, Stöger Eva, Capell Teresa, Christou Paul
Departament de Producció Vegetal i Ciència Forestal, Universitat de Lleida, Avenida Alcalde Rovira Roure, 191, Lleida, 25198, Spain.
Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3727-32. doi: 10.1073/pnas.0708841104. Epub 2008 Mar 3.
A series of small-molecule microbicides has been developed for vaginal delivery to prevent heterosexual HIV transmission, but results from human clinical trials have been disappointing. Protein-based microbicides, such as HIV-specific monoclonal antibodies, have been considered as an alternative approach. Despite their promising safety profile and efficacy, the major drawback of such molecules is the economy of large-scale production in mammalian cells, the current system of choice. Here, we show that an alternative biomanufacturing platform is now available for one of the most promising anti-HIV antibodies (2G12). Our data show that the HIV-neutralization capability of the antibody is equal to or superior to that of the same antibody produced in CHO cells. We conclude that this protein production system may provide a means to achieve microbicide ingredient manufacture at costs that would allow product introduction and manufacture in the developing world.
一系列用于阴道给药以预防异性间HIV传播的小分子杀菌剂已被研发出来，但人体临床试验的结果却令人失望。基于蛋白质的杀菌剂，如HIV特异性单克隆抗体，已被视为一种替代方法。尽管这类分子具有良好的安全性和有效性，但其主要缺点是在当前首选的哺乳动物细胞中大规模生产的经济性。在此，我们表明，一种替代生物制造平台现在可用于最有前景的抗HIV抗体之一（2G12）。我们的数据表明，该抗体的HIV中和能力等同于或优于在CHO细胞中产生的相同抗体。我们得出结论，这种蛋白质生产系统可能提供一种手段，以能够在发展中世界引入和生产产品的成本来实现杀菌剂成分的制造。
